Publication Name	World Journal of Gastroenterology
Manuscript ID	12064
Country	Denmark

Received	2014-06-20 08:51
Peer-Review Started	2014-06-20 20:52
To Make the First Decision	2014-07-09 12:09
Return for Revision	2014-07-17 15:47
Revised	2014-07-28 16:00
Second Decision	2014-09-05 16:49
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-09-05 17:18
Articles in Press	2014-09-05 17:28
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-11-06 09:42
Publish the Manuscript Online	2014-11-20 20:51

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Risk of infections associated with biological treatment in inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Nynne Nyboe Andersen and Tine Jess
Funding Agency and Grant Number
Corresponding Author	Nynne Nyboe Andersen, MD, Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen, Denmark. nyna@ssi.dk
Key Words	Inflammatory bowel disease; Biological treatment; Tumor necrosis factor-α inhibitors; Risk; Infections; Ulcerative colitis; Crohn’s disease
Core Tip	The use of tumor necrosis factor-α (TNF-α) inhibitors are increasing worldwide for the treatment of several chronic immune-mediated diseases as rheumatoid arthritis and inflammatory bowel disease (IBD). As the drugs are relatively new on the market, their long-term safety profile remains uncertain. In particular, a concern regarding an increased infections risk has been debated. In the current topic highlight, a brief overview of the current literature regarding the risk of infections in patients with IBD exposed to TNF-α inhibitors is outlined.
Publish Date	2014-11-20 20:51
Citation	Andersen NN, Jess T. Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol 2014; 20(43): 16014-16019
URL	http://www.wjgnet.com/1007-9327/full/v20/i43/16014.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i43.16014

Full Article (PDF)	WJG-20-16014.pdf
Full Article (Word)	WJG-20-16014.doc
Manuscript File	12064-Review.docx
Answering Reviewers	12064-Answering reviewers.pdf
Copyright License Agreement	12064-Copyright assignment.pdf
Peer-review Report	12064-Peer review(s).pdf
Scientific Misconduct Check	12064-CrossCheck.jpg
Scientific Editor Work List	12064-Scientific editor work list.pdf